Navigation Links
Quest Diagnostics to Speak at Barclays Capital Global Healthcare Conference
Date:3/9/2009

MADISON, N.J., March 9 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Barclays Capital Healthcare Conference in Miami on Tuesday, March 10, 2009. The Quest Diagnostics presentation is scheduled to begin at 9:00 a.m. Eastern Time.

During the conference, the company will reaffirm its 2009 guidance for revenue growth of approximately 3%, operating income to approach 18% of revenues, and earnings per diluted share from continuing operations of between $3.50 and $3.70.

The presentation will be webcast live during the conference and will be available to registered investors on the following site: http://cc.talkpoint.com/barc002/030909a_rb/?entity=104_3J1C75N and to the public on www.QuestDiagnostics.com/investor. In addition, the archived webcast will be available within 24 hours after the conclusion of the live event and will remain available until April 10, 2009.

Quest Diagnostics is the world's leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at www.q
'/>"/>

SOURCE Quest Diagnostics
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Safety of Labor-Delaying Drugs Questioned
2. Quest Diagnostics Again Named to FORTUNE Magazines Worlds Most Admired Companies List
3. FRC Action Questions President Obamas Choice of Gov. Sebelius for HHS
4. Presidents 2010 Budget Request Strongly Supports VA Programs
5. An Athletes First Question: Doc, When Can I Return?
6. Six Questions Consumers Should Ask About Genetic Tests
7. Virtual studies answer real questions
8. Findings raise new questions about evolution of hormones in mammals
9. Charleston Conducts Evaluation of an Opioid Symptoms Questionnaire
10. C4CC Education Fund Launches Discussion Forum for Consumers With Health Insurance Questions
11. SurgiQuest Announces FDA Approval for Smoke & Plume Evacuation for AirSeal Dynamic Pressure System(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 2Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 3Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 4Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 5Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 6Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 7Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 8Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 2Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 3Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 4Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 5Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 6Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 7Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 8Particle Sciences and IES Engineers Cooperate on High Potency Compound Handling Capabilities 2Particle Sciences and IES Engineers Cooperate on High Potency Compound Handling Capabilities 3NYU Langone Medical Center Study Shows VNS Therapy is a Safe and Effective Treatment for Refractory Epilepsy 62593 1NYU Langone Medical Center Study Shows VNS Therapy is a Safe and Effective Treatment for Refractory Epilepsy 62593 2NYU Langone Medical Center Study Shows VNS Therapy is a Safe and Effective Treatment for Refractory Epilepsy 62593 3Looking Ahead to AES 2009 3A New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 6746 1Looking Ahead to AES 2009 3A New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 6746 2Looking Ahead to AES 2009 3A New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 6746 3IntelliSoft Group Focuses on Protecting Customer Investment in Medical Credentialing Systems Budget Constraints and Forced Upgrades in Medical Cred 62589 1IntelliSoft Group Focuses on Protecting Customer Investment in Medical Credentialing Systems Budget Constraints and Forced Upgrades in Medical Cred 62589 2